Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin’s Corporate Quality Oversight Questioned In FDA Warning Letter

Executive Summary

Two-month inspection during pandemic highlighted cross-contamination risks and process validation shortfalls at New Jersey plant.

You may also be interested in...



The Quality Lowdown: Problems At Iso-Tex, Centaur, Biocon, Lupin And US Specialty

Hot, humid clean rooms, drug-caked equipment, stuck syringes, iffy contraceptives and iffy GMPs were among the pharmaceutical quality shortcomings that surfaced recently.

Boon For Lupin As FDA Upgrades Somerset Site Status

Looking to provide evidence of its extended measures to improve quality, compliance and oversight, Lupin has received positive news from the FDA for its US-based manufacturing facility in Somerset, New Jersey.

The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?

As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144568

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel